Cargando…
Is the right way to go in between?: Rimegepant as needed provides preventive benefit. A comment on: monthly migraine days, tablet utilization, and quality of life associated with rimegepant—post hoc results from an open label safety study (BHV3000–201)
In the study by Johnston et al., gepants were meant to be taken to treat emergent migraine. It is tempting to speculate what the effect would be if patients were instructed to take a gepant as needed (PRN) or even prior to headache onset. While the latter sounds irrational at first glance, several s...
Autores principales: | Gantenbein, Andreas R., Kleinschmidt, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061740/ https://www.ncbi.nlm.nih.gov/pubmed/36997843 http://dx.doi.org/10.1186/s10194-023-01565-6 |
Ejemplares similares
-
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
por: Johnston, Karissa, et al.
Publicado: (2022) -
Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
por: Powell, Lauren C., et al.
Publicado: (2022) -
ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020) -
Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
por: Blair, Hannah A.
Publicado: (2023) -
Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
por: Blair, Hannah A.
Publicado: (2023)